Biophytis S.A.

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

Biophytis is a clinical-stage biotechnology company specialized in the development of therapeutic products aimed at slowing degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in COVID-19 patients.

NASDAQ:BPTS

Biophytis

Last Close

0.34

08/11 16:24

Market Cap

3.05M

Beta: 1.17

Volume Today

75.61K

Avg: 90.69K

PE Ratio

−0.03

PFCF: −0.24

Analysis Not Available